Improving life after brain injury Need to talk? 0808 800 2244

Home News and campaigns News 2020

Headway welcomes findi...

Headway welcomes findings of trifluoperazine study Main Image

Headway welcomes findings of trifluoperazine study

Thu 14 May 2020

Headway has given a cautious welcome to the findings of a new study which found the antipsychotic drug trifluoperazine (TFP) to be successful in reducing swelling following brain injuries.

The new treatment, developed by scientists at Aston University in partnership with international academic institutions, works by counteracting the cells’ normal reaction to a loss of oxygen in the brain when trauma occurs.

Peter McCabe, Chief Executive of Headway – the brain injury association, said: “We welcome any research that could lead to an improvement of the treatment of brain injuries.

“Every three minutes someone in the UK is admitted to hospital with a head injury, the consequences of which can be devastating and last a lifetime, so it’s encouraging to hear about the findings of this study.

“We believe that further research is required to better understand the impact of this drug. Indeed, the study has identified potential adverse side effects, including links to depression, and this is something that would need to be explored and carefully monitored.

“We look forward to seeing how this research continues to progress.”


Share this page

Headway - the brain injury association is registered with the Charity Commission for England and Wales (Charity no. 1025852) and the Office of the Scottish Regulator (Charity no. SC 039992). Headway is a company limited by guarantee, registered in England no. 2346893.

© Copyright Headway 2020  -  Site designed and developed by MEDIAmaker